As filed with the Securities and Exchange Commission on June 5, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
CRISPR THERAPEUTICS AG
(Exact name of registrant as specified in its charter)
|
|
Switzerland |
Not applicable |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
|
Baarerstrasse 14 6300 Zug Switzerland +41 (0)41 561 32 79 (Address of principal executive offices) |
Not Applicable (Zip Code) |
CRISPR Therapeutics AG
2026 Stock Option and Incentive Plan
(Full title of the plan)
Samarth Kulkarni, Ph.D.
Chief Executive Officer
c/o CRISPR Therapeutics, Inc.
105 West First Street
South Boston, MA 02127
(Name and address of agent for service)
617-315-4600
(Telephone number, including area code, of agent for service)
Copies to:
|
|
Robert E. Puopolo Marishka DeToy Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 (617) 570-1000 |
James R. Kasinger 6300 Zug Switzerland +41 (0)41 561 32 79 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☒ |
Accelerated filer |
☐ |
|
|
|
|
Non-accelerated filer |
☐ |
Smaller reporting company |
☐ |
|
|
|
|
|
|
Emerging growth company |
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐